Lysophosphatidic acid (LPA)—a perspective marker in ovarian cancer.
To compare plasma lysophosphatidic acid (LPA) levels in ovarian cancer patients in women with benign ovarian tumors and in women with no ovarian pathology. We correlated clinico-pathological parameters with plasma LPA levels. Capillary electrophoresis with indirect ultraviolet detection was used to analyze the plasma LPA levels of 159 patients (81 patients with ovarian cancer, 27 women without ovarian or uterine pathologies, and 51 patients with benign ovarian tumors) during a 5-year period. Patients with ovarian cancer had a significantly higher plasma LPA level (n=81; median (med), 11.53 μmol/l; range, 1.78-43.21 μmol/l) compared with controls with no ovarian pathology (n=27; med, 1.86 μmol/l; range, 0.94-9.73 μmol/l), and patients with benign ovarian tumor (n=51; med, 6.17 μmol/l; range, 1.12-25.23 μmol/l; P<0.001). We found that plasma LPA levels were associated with the International Federation of Gynecology and Obstetrics stage. The histological subtype and grade of ovarian cancer did not influence the plasma LPA levels in this study. The plasma LPA level can be a useful marker for ovarian cancer, particularly in the early stages of the disease.
Department of Gynecology and Obstetrics, University Hospital, Sokolská 581, 500 05 Hradec Králové, Czech Republic. sedlakiva@seznam.cz
Iva
I
Sedláková
Jaroslava
J
Vávrová
Jindřich
J
Tošner
Ladislav
L
Hanousek
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000097:blood*; D016022:Case-Control Studies; D005260:Female; D006801:Humans; D008246:Lysophospholipids / Q000097:blood*; D008875:Middle Aged; D009367:Neoplasm Staging; D018297:Neoplasms, Cystic, Mucinous, and Serous / Q000097:blood* / Q000473:pathology; D010051:Ovarian Neoplasms / Q000097:blood* / Q000473:pathology; D012189:Retrospective Studies; D012680:Sensitivity and Specificity
D014408:Biomarkers, Tumor; D008246:Lysophospholipids; C032881:lysophosphatidic acid